Research Study

Past Study: InvestiGAIT

Study Status: CLOSED

Study Name: InvestiGAIT

Study Focus: Aging


Study Contact: To learn more, please call 1-877-854-8475 or fill out the Contact us form.

Study Purpose: The purpose of this study is to find out if the drug bimagrumab (BYM338) is safe and has beneficial (positive) effects in people with a lower than normal amount of muscle, as compared to placebo. To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the associated criteria:

• 70 years old or older

• Weight of at least 77 lbs

• BMI 15-32 kg/m2

• Self-reported mobility limitations, for example; difficulty walking, rising from a chair, orclimbing stairs.

Study Duration: up to 10 months

Study Commitment: The study consists of about 13 visits to the TRI-MD facility. The visits include:

• 1 Screening visit

• At least 12 Study visits

During the study,some of the procedures will include:

•Physical exam

• Blood collection

• ECG (Electrocardiogram)

• Physical function and strength tests

• DEXA (Dual-Energy Xray Absorptiometry)

• Study drug/Placebo IV infusion


Compensation offered? Yes This study is being conducted under the direction of Dr. Bret Goodpaster, at 301 East Princeton Street, Orlando, Florida 32804.